Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)
View forecast on Grants.gov →Forecasted — not yet open
- Posted
- August 13, 2026
- Closes
- See announcement
- Cost sharing
- No
- Instrument
- Cooperative Agreement
- Assistance listing
- 93.866
- Category
- Health
Program funding history
Awards made under Assistance Listing 93.866 across FY2024–FY2026, from public federal spending records.
- FY2024 obligated
- $3.8B
- FY2025 obligated
- $3.9B
- FY2026 (to date) obligated
- $2.4B
- Awards in window
- 12,121
Top recipients: Regents of the University of Michigan, Regents of the University of California, San Francisco, the, Washington University, the, The Trustees of Columbia University in the City of New York, University of Southern California
Source: USAspending.gov · refreshed August 2026
Synopsis
The National Institute on Aging (NIA) intends to publish a Notice of Funding Opportunity (NOFO) to solicit applications that propose pre-clinical and early-stage clinical (Phase I) development of novel small-molecule and biologic drug candidates that aim to prevent Alzheimer's disease (AD), slow its progression, or treat its cognitive and behavioral symptoms.
Through the NOFO, NIA is continuing the Alzheimer's Drug-Development Program (ADDP) with the aim of catalyzing drug development for AD. The ADDP is designed to provide funding support to academic and biotech researchers for preclinical drug development activities that can be conducted in their own laboratories or conducted in collaboration with contract research organizations that specialize in preclinical drug development activities. By supporting the most challenging and costly steps of drug development and seamlessly connecting preclinical drug development and first-in-human testing for drug candidates, the ADDP program seeks to:
- Continue to expand the number of investigational new drug candidates for a portfolio of emerging therapeutic targets;
- Continue to expand the therapeutic pipeline for AD with drug candidates targeting multiple underlying disease mechanisms that can be used as mono-therapy or as part of combination therapy; and
- Enable a precision medicine approach to AD drug development.
The NOFO will utilize the U01 activity code. Applications are not being solicited at this time. This notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects.
Who can apply
- State governments
- Public housing authorities/Indian housing authorities
- Native American tribal governments (Federally recognized)
- Independent school districts
- Public and State controlled institutions of higher education
- Special district governments
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- County governments
- Native American tribal organizations (other than Federally recognized tribal governments)
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- For profit organizations other than small businesses
- City or township governments
- Private institutions of higher education
Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;
How to apply
Applications go through the official government listing. Grants Radar links you straight to the source — applying is free.
New to federal funding? How to read an announcement · Who can apply · How grants work
Get grants like this every Tuesday — free
One email a week: the biggest new federal grants and what’s closing soon — the same list for everyone. Unsubscribe in one click.
Similar grants
- Feasibility Clinical Trials of Mind and Body Interventions for NCCIH High Priority Research Topics (R34 Clinical Trial Required)
- Investigator Initiated Clinical Trials of Complementary and Integrative Interventions Delivered Remotely or via mHealth (R01 Clinical Trial Required)
- Limited Competition: Small Grant Program for the NCATS Clinical and Translational Science Award (CTSA) Program (R03 Clinical Trial Optional)
- Dissemination and Implementation Research in Health (R01 Clinical Trial Optional)
- Dissemination and Implementation Research in Health (R21 Clinical Trial Optional)
- Dissemination and Implementation Research in Health (R03 Clinical Trial Not Allowed)
Same-day alerts, matched to you
The free digest is weekly — the same list for everyone. Members get an alert the day a matching federal grant posts: we read every new Grants.gov posting and score it, personalized to your organization. Free for 30 days, then $19/mo founding rate locked for life — the rate holds while your subscription stays active (Terms). Card required, cancel any time before day 31.
See pricing